Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just In: $EIDX SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Eidos Therapeutics, Inc. (Nasdaq - EIDX)
BALA CYNWYD, PA / ACCESSWIRE / October 5, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Eidos Therapeutics, Inc. ("Eidos" or the "Company") (NASDAQ:EIDX) for possible breaches of fiduciary duty and other vi...
NEWS: $EIDX Why Eidos Therapeutics Stock Is Skyrocketing Today
Shares of Eidos Therapeutics (NASDAQ: EIDX) were skyrocketing 41.1% higher as of 11:50 a.m. EDT on Monday. The huge gain came after BridgeBio Pharma (NASDAQ: BBIO) announced plans to acquire Eidos. BridgeBio already owns a major stake in Eidos. It's now seeking to buy th...
News; $EIDX (EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal?
(EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Oct. 5, 2020 SAN DIEGO , Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an i...
News: $EIDX CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...
News: $EIDX BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...
News: $EIDX Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares
Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal dated August 8, 2...
News: $EIDX INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or “the Company”) (NASDAQ: EIDX ) for violations of §§10(b) and 20(a) of the Secu...